The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 14, 2026
Filed:
Jan. 09, 2020
Applicants:
Ken-ichi Yamada, Fukuoka, JP;
Fuso Pharmaceutical Industries, Ltd., Osaka, JP;
Inventors:
Ken-Ichi Yamada, Fukuoka, JP;
Keiichi Yamamoto, Osaka, JP;
Assignee:
FUSO PHARMACEUTICAL INDUSTRIES, LTD., Osaka, JP;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/47 (2006.01); A23L 2/52 (2006.01); A23L 33/00 (2016.01); A23L 33/10 (2016.01); A61K 31/137 (2006.01); A61K 31/197 (2006.01); A61K 31/198 (2006.01); A61K 31/4045 (2006.01); A61K 31/407 (2006.01); A61K 31/4439 (2006.01); A61K 31/473 (2006.01); A61K 31/551 (2006.01); A61P 9/10 (2006.01); A61P 25/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/47 (2013.01); A23L 2/52 (2013.01); A23L 33/10 (2016.08); A23L 33/40 (2016.08); A61K 31/197 (2013.01); A61P 25/28 (2018.01); A23V 2002/00 (2013.01);
Abstract
The disclosures as described herein a pharmaceutical composition for preventing or treating a cerebrovascular disorder or a vascular dementia, or suppressing a progression of the diseases in a subject in need of the treatment and so on, the composition comprising one or more compounds selected from the following group, and a pharmaceutically acceptable carrier; and a method using the same. A group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine, indapamide, and the others.